Published by Josh White on 9th January 2020
(Sharecast News) - Respiratory disease-focussed pharmaceutical company Circassia Pharmaceuticals updated the market on its trading for the year ended 31 December on Thursday, announcing that it expected revenues for the year to fall in the mid-range of its previously issued guidance of between £60m and £65m.